Endostatin
- Generic Name
- Endostatin
- Drug Type
- Biotech
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Placebo and Paclitaxel-Carboplatin
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Protgen Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT01527864
- Locations
- 🇨🇳
Cancer hospital, Chinese academy of medical science, Beijing, Beijing, China
Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT01310478
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT01218594
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Phase 2
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT01192230
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2010-05-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 250
- Registration Number
- NCT01124253
- Locations
- 🇨🇳
The Lung Cancer Center of shanghai chest Hospital, Shanghai, China
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 1108
- Registration Number
- NCT00576914
- Locations
- 🇨🇳
The Lung Cancer Center of Cancer Hospital, Beijing, Beijing, China
rhEndostatin Protein Involving Pediatric Patients With Cancer
Phase 1
Terminated
- Conditions
- Solid Tumors
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00165373
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath